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Aims Succinate accumulates several-fold in the ischemic heart and is then rapidly oxidised 35 
upon reperfusion, contributing to reactive oxygen species (ROS) production by mitochondria. 36 
In addition, a significant amount of the accumulated succinate is released from the heart into 37 
the circulation at reperfusion, potentially activating the G-protein coupled succinate receptor 38 
(SUCNR1). However, the factors that determine the proportion of succinate oxidation or 39 
release, and the mechanism of this release, are not known.  40 
Methods and results To address these questions, we assessed the fate of accumulated 41 
succinate upon reperfusion of anoxic cardiomyocytes, and of the ischemic heart both ex vivo 42 
and in vivo. The release of accumulated succinate was selective and was enhanced by 43 
acidification of the intracellular milieu. Furthermore, pharmacological inhibition, or 44 
haploinsufficiency of the monocarboxylate transporter 1 (MCT1) significantly decreased 45 
succinate efflux from the reperfused heart. 46 
Conclusion Succinate release upon reperfusion of the ischemic heart is mediated by MCT1 47 
and is facilitated by the acidification of the myocardium during ischemia. These findings will 48 
allow the signalling interaction between succinate released from reperfused ischemic 49 
myocardium and SUCNR1 to be explored. 50 
Translational Perspectives In this study we demonstrate that succinate efflux upon 51 
reperfusion of the ischemic myocardium is mediated by the monocarboxylate transporter 1  52 
(MCT1) and is enhanced by the ischemic acidification of the heart. These findings are an 53 
important advance in understanding how succinate is released upon reperfusion of ischemic 54 
organs. While this pathway is therapeutically tractable, greater understanding of the effects of 55 
succinate release is required before exploring this possibility. 56 
 57 
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1. Introduction 62 
 63 
Succinate accumulates several-fold in a range of ischemic tissues, including the heart.1–5 64 
Upon reperfusion, the succinate levels very rapidly (<1.5 – 2 min) return to baseline values.3,4 65 
A proportion of this accumulated succinate is oxidised by the mitochondrial respiratory 66 
chain, contributing to the formation of the reactive oxygen species (ROS), superoxide 67 
(Figure 1).4 This ROS production initiates a cascade of damage that culminates in 68 
ischemia/reperfusion (I/R) injury.4 In addition to its oxidation, upon reperfusion a significant 69 
amount of the accumulated succinate is released from the heart into the circulation.2,6 The 70 
succinate accumulated during ischemia is thought to move from the mitochondria to the 71 
cytosol, catalysed by the dicarboxylate carrier (DIC) in exchange for malate.7 Therefore, 72 
upon reperfusion of the ischemic heart, the cytosolic succinate has two fates – it either re-73 
enters mitochondria as a respiratory substrate to drive ROS production, or effluxes from the 74 
cell (Figure 1). Efflux of succinate from the ischemic heart upon reperfusion has been 75 
demonstrated ex vivo in the mouse heart and in human hearts in vivo during primary 76 
percutaneous coronary intervention (PPCI) on ST-elevated myocardial infarction (STEMI) 77 
patients.2,6 However, the mechanism of succinate release is unknown. 78 
Succinate accumulation is a conserved signature of ischemia in different organs and 79 
species,1–5 suggesting that its release upon reperfusion may be a signal of tissue ischemia 80 
and/or damage. Furthermore, there is a G-protein coupled succinate receptor (SUCNR1) that 81 
can respond to the succinate released into the circulation (Figure 7).8–10 SUCNR1 is highly 82 
expressed on the surface of immune cells and its ligation has been associated with a range of 83 
both pro- and anti-inflammatory phenotypes, depending on context.8,11–13 In addition, 84 
succinate release into the circulation may have other effects in addition to signalling from 85 
ischemic tissue, for example succinate was shown to activate thermogenesis by brown 86 
adipose tissue.14 Together these findings suggest that succinate released from ischemic 87 
tissues into the circulation may promote a range of responses, such as the infiltration of 88 
immune cells and thereby contribute to the pathology and/or resolution of I/R injury (Figure 89 
7).6,9,15 90 
To address the mechanism of succinate release into the circulation during reperfusion, 91 
we assessed the efflux of succinate from ischemic cardiomyocytes, mouse hearts ex vivo and 92 
in vivo, and in a pig model of myocardial infarction (MI). We show that succinate was one of 93 
only a few metabolites released upon reperfusion of the ischemic heart. Furthermore, 94 
succinate efflux was mediated by the monocarboxylate transporter 1 (MCT1) and 95 
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acidification of the myocardium during ischemia enhanced release upon reperfusion. This 96 
understanding of how succinate is released upon reperfusion of ischemic organs has 97 
translational implications for targeting succinate signalling following MI. 98 
 99 
2. Methods 100 
All experiments were performed under UK Home Office Licences and conducted according 101 
to the Animals Scientific Procedures Act 1986 (UK) and directive 2010/63/EU of the 102 
European Parliament guidelines on the protection of animals used for scientific purposes. All 103 
experiments were approved by the Institutional Animal Welfare and Ethical Review Body. 104 
C57BL/6J male mice (~25 g, 8-12 weeks old, n = 102) were from Charles River, UK. The 105 
MCT1+/- mice (8-12 weeks old) were initially generated by homologous recombination16 and 106 
bred to produce MCT+/- and corresponding MCT+/+ littermate controls. Female Wistar rats 107 
(~250 g, 10-12 weeks old) were from Charles River, UK. All mice and rats were kept in 108 
individually ventilated cages with a 12 h light-dark cycle, controlled humidity and 109 
temperature (20–22 °C), fed standard chow and water ad libitum. Experiments in pig were 110 
carried out under Home Office Project Licence No 7008975 at the University of Bristol 111 
Translational Biomedical Research Centre (TBRC), Bristol, UK, and advanced facility for 112 
large animal research (http://www.bristol.ac.uk/health-sciences/research/tbrc/). 113 
 114 
For Langendorff perfusions, mice were administered terminal anaesthesia via intra-peritoneal 115 
pentobarbitone injection (~140 mg/kg body weight). For in situ ischemia/reperfusion, mice 116 
were anesthetised with isofluorane (2 x minimum alveolar concentration and O2 at 2 L/min 117 
Abbott Laboratories, US) before performing a laparotomy and administering 100 µl heparin 118 
bolus (100 iU; Leo Pharma A/S, Denmark). Mice were culled via exsanguination by division 119 
of the abdominal inferior vena cava (IVC) and aorta. For isolation of adult cardiomyocytes, 120 
mice were culled by cervical dislocation (no anaesthetic used). For isolation of rat heart 121 
mitochondria, rats were culled by cervical dislocation (no anaesthetic used). In porcine 122 
myocardial infarction model, landrace female pigs were premedicated with intramuscular 123 
injection of ketamine (10 mg/kg) and dexmedetomidine (15 µg/kg); for general anaesthesia, 124 
IV boluses of propofol (1 mg/kg) were used followed by isoflurane in oxygen with the 125 
vaporiser set at 2% for maintenance. At the end of the experiment, pigs were terminated by 126 
administration of 2 litres cold cardioplegia solution via the aorta at a delivery pressure of 300 127 
mmHg. 128 
2.1 Animal ischemia/reperfusion experimental models 129 
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2.1.1. Langendorff-perfused mouse hearts 130 
Mice were administered terminal anaesthesia via intra-peritoneal pentobarbitone injection 131 
(~140 mg/kg body weight). While anaesthetics such as pentobarbitone can affect 132 
mitochondrial function, in our experiments the effects of inhibitors and other interventions 133 
are compared with control using identical anaesthetic regimes. Beating hearts were rapidly 134 
excised, cannulated and perfused in isovolumic Langendorff mode at 80 mm Hg pressure 135 
maintained by a STH peristaltic pump controller feedback system (AD Instruments, UK), 136 
with phosphate-free Krebs-Henseleit (KH) buffer continuously gassed with 95% O2/5% CO2 137 
(pH 7.4, 37 °C) containing (in mM): NaCl (116), KCl (4.7), MgSO4.7H2O (1.2), NaHCO3 138 
(25), CaCl2 (1.4), glucose (11). Cardiac function was assessed using a fluid-filled cling-film 139 
balloon inserted into the left ventricle (LV) connected via a line to a pressure transducer and 140 
a Powerlab system (AD Instruments, UK). The volume of the intraventricular balloon was 141 
adjusted using a 1.0 mL syringe to achieve an initial LV diastolic pressure (LVDP) of 4–9 142 
mmHg. Functional parameters (systolic pressure, end diastolic pressure, heart rate, coronary 143 
flow, perfusion pressure) were recorded using LabChart software v.7 (AD Instruments, UK) 144 
throughout the experiment. LVDP was calculated from the difference between systolic (SP) 145 
and diastolic pressures (DP). After 20 min equilibration, hearts were subjected to 20 min 146 
global ischemia prior to reperfusion. Perfusate was collected in 1 min intervals for the first 6 147 
min of reperfusion and snap frozen in liquid nitrogen. Where inhibitors were used, these were 148 
added in the reperfusion buffer, with the heart reperfused for 6 min containing the inhibitors 149 
throughout (unless specified otherwise). Hearts were immediately snap frozen using 150 
Wollenberger tongs pre-cooled in liquid nitrogen either after equilibration, ischemia or the 151 
reperfusion period (6 min) and stored at –80 °C until further analysis. 152 
 153 
2.1.2. In situ mouse heart ischemia/reperfusion 154 
Mice were anesthetised with isofluorane (2 x minimum alveolar concentration and O2 at 2 155 
L/min Abbott Laboratories, US) before performing a laparotomy and administering 100 µl 156 
heparin bolus (100 iU; Leo Pharma A/S, Denmark). Mice were exsanguinated by division of 157 
the abdominal inferior vena cava (IVC) and aorta. Global ischemia was maintained within the 158 
body for 20 min, with physiological temperature (37 °C) maintained using a core-temperature 159 
controlled heating-mat. During ischemia, fine borosilicate tubing was inserted into the root of 160 
the aorta and a collection tube inserted into the IVC lumen. Immediately before reperfusion, 161 
the superior vena cava, pulmonary artery and hemiazygos vein were clamped to prevent back 162 
flow from the right atrium on flush. The heart was retrograde perfused with phosphate-free 163 
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KH buffer (37 °C) at a flow rate of 1 ml/min. Perfusate was collected at 1 min intervals for 6 164 
min and the heart clamp frozen. 165 
 166 
2.1.3. Porcine myocardial infarction model 167 
Landrace female pigs (n=3; 5-6 months, median weight 62.5 kg) were premedicated with 168 
intramuscular injection of ketamine (10 mg/kg) and dexmedetomidine (15 µg/kg); for general 169 
anesthesia, IV boluses of propofol (1 mg/kg) were used followed by isoflurane in oxygen 170 
with the vaporiser set at 2% for maintenance. Mechanical ventilation targets of tidal volume 171 
of 10-20 ml/kg and a respiratory rate of 10-20 breaths per minute were used, aiming for end 172 
tidal carbon dioxide between 35 and 45 mmHg. Full monitoring included electrocardiogram, 173 
invasive arterial blood pressure, temperature, saturation and central venous pressure via a line 174 
in the central jugular vein (JV). Following median sternotomy and heparinization (150 IU/kg) 175 
a 5-0 prolene suture was passed around the proximal left anterior descending artery (LAD) 176 
just distal to the first diagonal branch; a catheter was inserted into the coronary sinus (CS) 177 
under direct vision and a sampling line was inserted into the aortic root (AR). Under stable 178 
conditions the LAD was gently snared to start a period of 60 min of ischemia, after which the 179 
snare was released to allow reperfusion for another period of 60 min before termination and 180 
myocardial sampling. Blood was drawn serially from JV, CS, and AR at the following time 181 
points: baseline, before intervention and at 5, 15, 30, and 60 min during ischemia and at 1, 3, 182 
5, 15, 30, and 60 min of reperfusion. 183 
 184 
2.1.4. In vivo murine myocardial infarction model 185 
The left anterior descending (LAD) coronary artery was occluded to induce MI in an acute 186 
open chest, in situ mouse model as described previously17 to assess the effects of AR-187 
C141990 on I/R injury. Briefly, mice were anaesthetized by administration of sodium 188 
pentobarbital (70 mg/kg intraperitoneally), endotracheally intubated, ventilated with 3 cm 189 
H2O positive end expiratory pressure and kept at 37 °C using a rectal thermometer-controlled 190 
heatpad (TCAT-2LV, Physitemp, USA). Ventilation frequency was maintained at 110 191 
breaths/min, with tidal volume between 125 and 150 µl. The heart was exposed and a suture 192 
was placed around the prominent branch of the LAD and passed through a small plastic tube 193 
used to initiate ischemia by pressing the tube against the heart surface to occlude the LAD. 194 
Mice were subjected to 30 min of ischemia and 120 min of reperfusion, after reperfusion, 195 
hearts were stained with Evans Blue and 2% triphenyltetrazolium chloride (TTC) and blindly 196 
analyzed by an independent researcher. 197 
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2.2 Cardiomyocyte ischemia/reperfusion model 198 
2.2.1. Isolation of adult primary mouse cardiomyocytes 199 
Adult primary mouse cardiomyocytes were isolated as described previously.18 Mice were 200 
culled by cervical dislocation before rapidly excising the heart and cannulating via the aorta 201 
in ice-cold, sterile perfusion buffer (in mM: NaCl (113), KCl (4.7), KH2PO4 (0.6), Na2HPO4 202 
(0.6), MgSO4.7H2O (1.2), NaHCO3 (12), KHCO3 (10), HEPES sodium salt (0.922), taurine 203 
(30), 2,3-butanedione monoxime (10) and glucose (5.5)). Hearts were retrogradely perfused 204 
for 5 min with perfusion buffer (37 °C) to clear residual blood, then the hearts were digested 205 
by perfusing digestion buffer (30 ml perfusion buffer supplemented with 5 mg Liberase 206 
(Roche, UK) and 12.5 µM CaCl2) for 20 min. After digestion, the heart was removed from 207 
the cannula and carefully broken apart with tweezers and gentle pipetting in 4 ml digestion 208 
buffer. The cell suspension was transferred to a 15 ml centrifuge tube before making up to 10 209 
ml with stop buffer (37 °C) (10% [v/v] fetal bovine serum [FBS] in perfusion buffer) and 210 
allowed to pellet by gravity for 10 min at RT. After pelleting, the supernatant was removed 211 
and the cells were resuspended in sequentially increasing Ca2+ concentrations (62 µM, then 212 
212 µM, then 1 mM) in 5 ml stop buffer. Cells were subsequently resuspended in M199 213 
media (Gibco, Thermo Fisher Scientific) supplemented with 2 mM L-carnitine, 5 mM 214 
creatine, 5 mM taurine, 25 µM blebbistatin, 100 IU/ml penicillin and 100 IU/ml streptomycin 215 
and plated (1 x 105 cells/dish) in laminin-coated (0.1 mg/ml from Engelbreth-Holm-Swarm 216 
murine sarcoma basement membrane; Sigma Aldrich, UK) glass dishes. 217 
 218 
2.2.2 Anoxic cardiomyocyte incubations 219 
Anoxic incubations were carried out using an anaerobic chamber (0.4 ppm O2; Belle 220 
Technologies, UK). Equipment and solutions were degassed overnight in the transfer 221 
compartment of the anoxic chamber before the experiment was performed. Experiments were 222 
performed in Tyrode’s buffer (in mM: NaCl (137), KCl (5.4), MgCl2 (0.4), HEPES (10), 223 
Glucose (10), CaCl2 (1), pH 7.4). The MCT1 inhibitor AR-C141990 (Tocris, Biotechne) was 224 
used at a concentration of 10 µM in Tyrode’s buffer. Cardiomyocytes were plated (1 x 105 225 
cells/plate), washed once with Tyrode’s buffer (37 °C) before 2 ml fresh Tyrode’s buffer 226 
were added to each dish. Anoxia was induced for different time points by placing dishes in 227 
the anaerobic chamber on a 37 °C heat block, before the cells were lysed under anoxia, 228 
transferred to Eppendorf tubes and snap frozen on dry ice. Cells were reperfused by removing 229 
from the anaerobic chamber, replacing buffer with fresh Tyrode’s buffer and incubating (37 230 
°C, 15 min) before lysing cells for subsequent succinate analysis. 231 
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 232 
2.3 Metabolite measurement by mass spectrometry 233 
2.3.1. Succinate extraction  234 
For tissue samples, frozen tissues were weighed out on dry ice to achieve approximately 25 235 
mg of each tissue sample. Tissues were extracted with 25 µl/mg MS extraction buffer (50% 236 
[v/v] methanol, 30% [v/v] acetonitrile and 20% [v/v] H2O), supplemented with 1 nmol of 237 
[13C4]-succinate (Sigma Aldrich, UK) in a pre-chilled Precellys tube (Hard tissue 238 
homogenising CK28-R – 2 ml; Bertin Instruments, France). Tissues were homogenised using 239 
a Precellys 24 tissue homogeniser (6,500 rpm, 15 s; Bertin Instruments, France) and then 240 
immediately placed back on dry ice for 5 min. Samples were re-homogenised (6,500 rpm, 15 241 
s) and again placed on dry ice to cool before agitating in a shaking heat block (1,400 rpm, 15 242 
min, 4 °C; Thermo Fisher Scientific, UK) in a cold room (4 °C) and then incubating (-20 °C, 243 
1 h). Samples were subsequently centrifuged (17,000 x g, 10 min, 4 °C) and the supernatant 244 
transferred to a pre-chilled microcentrifuge tube and re-centrifuged (17,000 x g, 10 min, 4 245 
°C). The resulting supernatants were transferred to pre-cooled MS vials which were stored at 246 
-80 °C until analysis for succinate by liquid chromatography- tandem mass spectrometry 247 
(LC-MS/MS). 248 
For perfusate from the Langendorff heart and plasma samples, the perfusate or plasma 249 
was centrifuged (17,000 x g, 10 min, 4 °C) before extracting 50 µl in 750 µl MS extraction 250 
buffer supplemented with 1 nmol [13C4]-succinate. The samples were agitated in the cold 251 
(1,400 rpm, 15 min, 4 °C; Thermo Fisher Scientific, UK) before incubating (-20 °C, 1 h). The 252 
samples were centrifuged (17,000 x g, 10 min, 4 °C), then the supernatant transferred to a 253 
new tube and recentrifuged. The clear supernatant was transferred to MS vials and stored at -254 
80 °C until analysis. 255 
For adult primary cardiomyocytes, cardiomyocytes were extracted in 500 µl MS 256 
extraction buffer supplemented with 1 nmol [13C4]-succinate and agitated in the cold (1,400 257 
rpm, 15 min, 4 °C; Thermo Fisher Scientific, UK) before incubating (-20 °C, 1 h). The 258 
samples were centrifuged (17,000 x g, 10 min, 4 °C), then the supernatant transferred to a 259 
new tube and recentrifuged. The clear supernatant was transferred to MS vials and stored at -260 
80 °C until analysis. 261 
 262 
2.3.2. Quantification of succinate 263 
LC-MS/MS analysis of succinate was performed using an LCMS-8060 mass spectrometer 264 
(Shimadzu, UK) with a Nexera X2 UHPLC system (Shimadzu, UK). Samples were stored in 265 
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a refrigerated autosampler (4 °C) before injection of 5 μl using a 15 μl flowthrough needle. 266 
Separation was achieved using a SeQuant® ZIC®-HILIC column (3.5 μm, 100 Å, 150 x 2.1 267 
mm, 30 °C column temperature; MerckMillipore, UK) with a ZIC®-HILIC guard column 268 
(200 Å, 1 x 5mm). A flow rate of 200 μl/min was used with mobile phases of Buffer A: 10 269 
mM ammonium bicarbonate and Buffer B: 100% acetonitrile. A gradient of 0-0.1 min, 80% 270 
MS buffer B; 0.1-4 min, 80%-20% B; 4-10 min, 20% B, 10-11 min, 20%-80% B; 11-15 min, 271 
80% B was used. The mass spectrometer was operated in negative ion mode with multiple 272 
reaction monitoring (MRM) and spectra were acquired using Labsolutions software 273 
(Shimadzu, UK), with compound quantities calculated from relevant standard curves in MS 274 
extraction buffer and comparing against [13C4]-succinate internal standard. 275 
2.3.3. Metabolomic analysis by LC-MS 276 
Samples were extracted as for succinate quantification but 13C-succinate omitted and 5 µM 277 
d8-valine added instead. LC-MS analyses were performed on a Q Exactive Orbitrap (Thermo 278 
Scientific) mass spectrometer coupled to an Ultimate 3000 UHPLC system (Dionex). The 279 
liquid chromatography system was fitted with either a ZIC-HILIC column (150 mm × 4.6 280 
mm) or a ZIC-pHILIC column (150 mm × 2.1 mm) and respective guard columns (20 mm × 281 
2.1 mm) (all Merck, Germany). The metabolites were eluted with previously described 282 
gradients.19 The mass spectrometer was operated in full MS and polarity switching mode. 283 
Samples were randomised in order to avoid bias due to machine drift and processed blindly. 284 
The acquired spectra were analysed using XCalibur Qual and XCalibur Quan Browser 285 
software (Thermo Fisher Scientific) by referencing to an internal library of compounds. 286 
 287 
2.4 Isolation of rat heart mitochondria 288 
Rat heart mitochondria (RHM) were isolated as described previously.20 Briefly, freshly 289 
excised rat hearts were homogenised in STEB buffer (250 mM sucrose, 5 mM Tris, 1 mM 290 
EGTA, 0.1% [w/v] BSA, pH 7.4) using a dounce homogeniser. Homogenates were 291 
centrifuged (3,000 x g, 5 min, 4 °C) to pellet nuclei and unbroken cells. The resulting 292 
supernatant was then centrifuged (10,000 x g, 10 min, 4 °C) to pellet mitochondria. Pelleted 293 
mitochondria were resuspended in STEB buffer and re-centrifuged (10,000 x g, 10 min, 4 294 
°C). The pelleted mitochondria were resuspended in STEB buffer with the BSA omitted (400 295 
µl/heart) and the mitochondrial protein quantified by BCA assay (Thermo Fisher Scientific). 296 
 297 
2.5 Measurement of ROS production by RET 298 
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ROS production by RET was measured by following the conversion of Amplex Red to 299 
resorufin.20 Isolated RHM were incubated in KCl buffer (120 mM KCl, 10 mM HEPES, 1 300 
mM EGTA, pH 7.4; 37 °C) supplemented with Amplex Red (12.5 µM; Invitrogen, Thermo 301 
Fisher Scientific), horseradish peroxidase (20 µg/ml), BSA (200 µg/ml), superoxide 302 
dismutase (40 µg/ml) and succinate (0-10 mM) in a 96-well plate. Resorufin fluorescence 303 
was detected by ex= 570 nm and em= 585 and calibrated against known concentrations of 304 




2.6 Statistics and experimental design 309 
All data in figures are presented as mean ± S.E.M., unless stated otherwise in the figure 310 
legend. Statistical analysis was performed using either one or two-way ANOVA with the 311 
suitable post-hoc correction for multiple comparisons described in the figure legend. Where 312 
only two groups were compared, statistical significance was assessed by two-tailed Student’s 313 
unpaired t-test. A p value of less than 0.05 was considered significant. Statistics were 314 
calculated in Prism 8.0 software (GraphPad Software Inc, USA). 315 
 316 
3. Results  317 
 318 
3.1 Succinate efflux upon reperfusion of an ex vivo ischemic heart 319 
To quantify succinate efflux from the ischemic heart upon reperfusion, we used the 320 
Langendorff isolated heart perfusion model. Mouse hearts following 20 min functional 321 
equilibration (LVDP 94 ± 3 mmHg, heart rate 453 ± 20 beats/minute, coronary flow 3.5 ± 322 
0.14 mean±S.E.M., n=17) were then exposed to 20 min global, no-flow ischemia, followed 323 
by reperfusion with oxygenated perfusion buffer (Figure 2A). Langendorff hearts exposed to 324 
ischemia led to a 14-fold increase in succinate levels (Figure 2B), comparable to the 325 
succinate accumulation seen previously in the ischemic heart in vivo.4,5 Upon subsequent 326 
reperfusion, tissue succinate levels returned to baseline (Figure 2B). Halving the ischemic 327 
time decreased succinate accumulation, but following reperfusion the levels of succinate 328 
were the same (Figure 2B). To see if any of the succinate that had accumulated during 329 
ischemia was released from the heart upon reperfusion, we next measured succinate in the 330 
coronary effluent immediately after reperfusion (Figure 2A). Succinate was released from the 331 
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myocardium into the circulation over the first two min of reperfusion, with little further 332 
release after 3 min (Figure 2C). Note that the quantification of succinate release is 333 
normalised to perfusate volume and is thus independent of the flow rate. Comparing the total 334 
amount of succinate in the perfusate to that in the heart at the onset of ischemia, and 335 
correcting for baseline levels, showed that about half of the succinate accumulated during 336 
ischemia was released (Figures 2C-D), as was shown previously by Brookes and colleagues.6 337 
To confirm that this succinate efflux was largely from the cardiomyocytes, we used a murine 338 
primary adult cardiomyocyte model exposed to anoxia and reperfusion. Succinate 339 
accumulated significantly in anoxic cardiomyocytes and returned to baseline levels upon 340 
reperfusion (Figure 2E). After reperfusion, 1.3 ± 0.25 nmol succinate/105 cells (mean ± 341 
SEM, n = 6) was released into the incubation medium. This succinate release is about 60% of 342 
that accumulated within the cardiomyocytes during ischemia (corrected for succinate 343 
remaining after reperfusion; Figure 2E), and is consistent with the amount released from the 344 
heart upon reperfusion (Figures 2C-D). 345 
 346 
3.2 Dependence of ROS production by RET on succinate concentration 347 
In our ex vivo system we found that after 20 min global ischemia, the level of succinate per 348 
heart increased to about 360 – 400 nmol succinate/heart, while in a previous study we found 349 
that 30 min global ischemia of the heart in situ leads to ~800 nmol succinate/heart.5 As the 350 
mouse hearts used in these studies weigh ~184 ± 16 mg (n = 8, mean ± SEM), this 351 
corresponds to 2 - 4 µmol succinate/g wet weight. The water content of the rodent heart is 352 
615 µl/g wet weight intracellular and 174 µl/g wet weight extracellular.21 Assuming that the 353 
succinate stays within the cells during ischemia and is distributed roughly equally throughout 354 
the cell, this corresponds to an intracellular succinate concentration of 3-6 mM at the onset of 355 
reperfusion. Even if during ischemia the succinate was also equally distributed between the 356 
intracellular and extracellular water, this would still give an intracellular succinate 357 
concentration of 2.5-5 mM at the onset of reperfusion. The level of succinate in the normoxic 358 
mouse hearts here is 22 ± 3 nmol/heart (Mean ± SEM n = 5) and previously we reported a 359 
succinate level in the normoxic mouse heart of 34 nmol/heart.5 This corresponds to normoxic 360 
succinate levels of 120 - 185 nmol/g wet weight or an intracellular succinate concentration of 361 
195 - 300 µM. Thus, even if we assume that the efflux of ~50% of the intracellular succinate 362 
occurred immediately upon reperfusion, this would still leave mitochondria exposed to 1.5 – 363 
3 mM succinate at the onset of reperfusion, decreasing down to ~ 200 - 300 µM after 2-3 364 
min. To see if these levels of succinate were sufficient to drive RET at complex I, we 365 
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determined the dependence of complex I ROS production by RET in isolated heart 366 
mitochondria on succinate concentration (Figure 2F). This showed that RET production 367 
driven by succinate saturated at ~ 4 mM with a half maximal effective concentration (EC50) 368 
of ~ 1 mM (Figure 2F). This ROS production was largely inhibited by the complex I 369 
inhibitor rotenone, which blocks RET but does not affect ROS production at complex III. 370 
This is consistent with the protective effect of rotenone on IR injury/infarct size and suggests 371 
that the ROS production measured here is essentially all generated by RET at complex I. 372 
Thus, the level of succinate present within the ischemic heart at the onset of reperfusion is 373 
more than adequate to generate ROS by RET and this level of succinate must decrease by 374 
~80% before substantially affecting RET. Thus, the efflux of succinate from the tissue upon 375 
reperfusion does not impact on its ability to drive RET and cause pathological I/R injury.  376 
 377 
3.3 Selectivity of succinate release upon reperfusion 378 
To determine whether the succinate release from the heart was selective, or part of a general 379 
metabolite release due to tissue damage upon reperfusion, the metabolome of the perfusate 380 
from the Langendorff hearts was assessed (Figure 3A). For this, we could quantify the levels 381 
of 47 metabolites in the perfusate from the normoxic heart under equilibration, as well as in 382 
the perfusate during the first 3 min reperfusion of the ischemic heart (Figure 2A). We 383 
calculated the cardiac release ratio,2 the difference in metabolite levels between reperfusion 384 
and normoxia, normalised to the levels in the normoxic effluent (Figure 3A). This showed 385 
that only a few of the 47 metabolites measured were released upon reperfusion. To assess this 386 
further, we plotted the differences in metabolites in the perfusate between reperfusion and 387 
normoxia (Figure 3B). This demonstrated that only 10 metabolites showed a statistically 388 
significant release upon reperfusion. Among these were nicotinamide and the adenine 389 
nucleotide breakdown products hypoxanthine, adenine and inosine which are known to 390 
accumulate during ischemia.4,5,22 These metabolites are all neutral so they may diffuse 391 
passively through the cell membrane.23 In contrast, the other metabolites released - succinate, 392 
lactate and some amino acids – are charged and will require transporters to leave the cell 393 
upon reperfusion. Among charged substrates the cardiac release ratio was highest for 394 
succinate (Figure 3A), indicating that succinate is a major charged metabolite released upon 395 
reperfusion of the ischemic tissue probably via a selective transport pathway.  396 
As the Langendorff heart is perfused with an oxygenated, hyperglycaemic crystalloid 397 
buffer, we were uncertain how this might affect succinate accumulation, efflux and 398 
consumption upon reperfusion compared to the in vivo situation. To address this potential 399 
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concern, we assessed mouse hearts that were rendered ischemic in situ, prior to which they 400 
had been supplied with normal blood. To do this we induced global no-flow ischemia by 401 
exsanguination and then left the heart in the body for 20 min maintained at 37˚C. Then, the 402 
blood vessels were clamped and the heart was flushed with Krebs buffer and the perfusate 403 
collected. During global in situ ischemia we found significant accumulation of succinate 404 
(Figure 4A) and flushing the heart with oxygenated buffer led to a return to baseline levels of 405 
tissue succinate (Figure 4A). Measurement of succinate in the perfusate following flushing 406 
showed loss of succinate from the heart to the perfusate over the first 2-3 min reperfusion 407 
(Figure 4B), very similar to that for the Langendorff hearts. Comparing the total amount of 408 
succinate released with that present at the onset of ischemia and correcting for baseline levels 409 
showed that about 33% of the succinate that was present in the tissue at the end of ischemia 410 
was released upon flushing (Figure 4C). Thus, the succinate efflux seen in the ex vivo 411 
perfused heart is replicated by the more physiological in situ mouse heart.  412 
 To extend this analysis to a large animal model closer in size to human, we used a pig 413 
MI model of ischemia/reperfusion in which a 5-0 prolene suture was passed around the 414 
coronary artery and gently snared to block blood flow and to hold the heart ischemic for 60 415 
min and then released to reperfuse the ischemic tissue with oxygenated blood (Figure 4D). 416 
We assessed the efflux of succinate from the ischemic tissue into the coronary sinus, which 417 
reflects any metabolites released by the ischemic myocardium upon reperfusion, as well as 418 
that in the aortic root and in the jugular vein (Figure 4E; Supplementary material online, 419 
Figure S1). Upon reperfusion, there was a large increase in the succinate levels in the 420 
coronary sinus during the first 5 min reperfusion (Figure 4E), but not in the blood from the 421 
aortic root or jugular vein (Supplementary material online, Figure S1). To understand 422 
whether the levels of succinate released from the pig heart during reperfusion were 423 
significant compared to other metabolites, we measured the levels of 40 metabolites in the 424 
coronary sinus upon reperfusion and in the aortic root, enabling us to generate a cardiac 425 
release ratio (Figure 4F). This showed that only a few metabolites were released upon 426 
reperfusion of the ischemic heart tissue of pigs undergoing myocardial infarction and that 427 
prominent among them was succinate (Figure 4F). 428 
 429 
3.4 Succinate efflux can be inhibited 430 
The charged nature of succinate at physiological pH (pKa 4.2 and 5.6) and the selectivity of 431 
its efflux upon reperfusion of ischemic tissue suggests that its release is carrier mediated. To 432 
assess this hypothesis, we measured the effect on succinate efflux of the general succinate 433 
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transport inhibitors succimer and 2-phenylsuccinate, which are structurally similar to 434 
succinate (Figure 5A).24,25 Both these inhibitors decreased succinate efflux (Figure 5B), with 435 
a concomitant increase in succinate retention within the heart at the end of the reperfusion 436 
period (Supplementary material online, Figure S2).  437 
 438 
3.5 Succinate efflux is enhanced by the plasma membrane proton gradient 439 
The pH of the ischemic myocardium can decrease to ~6.5, compared to a pH of 7.4 for the 440 
heart perfusate.26,27 Hence, during reperfusion of the ischemic heart there will be a pH 441 
gradient of ~1 pH unit across the plasma membrane, acidic inside. As many metabolite 442 
transport processes are coupled to proton movement, we next assessed whether this pH 443 
gradient affects succinate efflux.28,29 To do this, we reperfused the ischemic heart with pH 6 444 
perfusion buffer to abolish the pH gradient (Figure 5C). Strikingly, this intervention greatly 445 
decreased succinate efflux (Figure 5C). To further assess the role of the pH gradient in 446 
succinate efflux we used a range of ionophores - gramicidin (H+, Na+, K+), monensin (H+, 447 
Na+) and nigericin (H+, K+), all of which can disrupt the plasma membrane pH gradient 448 
(Figure 5D). As these ionophores are all large hydrophobic molecules they act by inserting 449 
into the plasma membrane and are unlikely to redistribute to intracellular membranes such as 450 
the mitochondrial inner membrane over the timescale of these experiments.30 Thus, their 451 
effects are primarily due to disruption to the plasma membrane pH gradient. All these 452 
ionophores significantly decreased succinate efflux (Figure 5E). These ionophores are large 453 
hydrophobic molecules which are unlikely to migrate from the plasma membrane to disrupt 454 
mitochondrial membranes. In contrast use of the small protonophores FCCP and DNP 455 
significantly disrupted cardiac function (data not shown). We conclude that succinate efflux 456 
upon reperfusion of the ischemic heart is greatly enhanced by the pH gradient.  457 
 458 
3.6 Succinate efflux from the reperfused ischemic heart is mediated by MCT1 459 
The above data show that succinate efflux upon reperfusion of the ischemic heart is carrier-460 
mediated and enhanced by a pH gradient. Monocarboxylate transporter 1 (MCT1), which 461 
usually transports lactate in symport with a proton, is a potential carrier for this process.28,31,32 462 
As the first succinate pKa is ~5.6,33 at the pH within ischemic tissues (~6.5)26,27 about 10% of 463 
the succinate in the myocardium would be in the monocarboxylate form, which may be 464 
transported by MCT1.6,28,34 Supporting this possibility, expressing MCT1 in Xenopus oocytes 465 
led to succinate uptake into the cells, but only when incubated in a medium at acidic (pH ~6) 466 
pH.28 Furthermore, MCT1 is highly expressed in heart tissue.16 467 
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To assess whether MCT1 could mediate succinate efflux in the reperfused ischemic 468 
heart, we included lactate in the perfusion buffer to inhibit the activity of MCT1. This 469 
decreased succinate efflux (Figure 6A). Next, we reperfused ischemic hearts with AR-470 
C141990, a selective MCT1 inhibitor (MCTi),35,36 which led to a dose-dependent decrease in 471 
succinate efflux when added to the reperfusion buffer (Figure 6B). A similar effect was seen 472 
when hearts were administered the MCTi before ischemia (Figure 6B), which did not alter 473 
the ischemic levels of succinate (Supplementary material online, Figure S3). MCTi also 474 
enhanced succinate retention within the reperfused tissue (Supplementary material online, 475 
Figure S4). Succinate efflux was also reduced by MCT1 inhibition with MCTi, when it was 476 
added upon reoxygenation of anoxic cardiomyocytes. Here it decreased succinate efflux by 477 
about 90% from 1.28 ± 0.25 to 0.14 ± 0.02 nmol succinate/105 cells (mean ± SEM, n = 6).  478 
To confirm that MCT1 mediates succinate efflux from the ischemic heart upon 479 
reperfusion, we utilised the MCT1+/- mouse model.16,37,38 Whilst the MCT1-/- mouse is 480 
embryonic lethal, MCT1+/- mice have ~40% reduction in the expression of MCT1 in the 481 
heart16 and have no obvious phenotype in normoxic conditions when compared to MCT+/+ 482 
controls.16,37,38 While the levels of succinate in the MCT1+/- and MCT+/+ hearts were the same 483 
after 20 min ischemia (Supplementary material online, Figure S3), succinate efflux from 484 
reperfused MCT1+/- hearts was significantly lower than that of MCT1+/+ control hearts 485 
(Figure 6C). The levels of succinate retained in the heart after 6 min of reperfusion did not 486 
differ between the MCT1+/+ and MCT1+/- hearts (Supplementary material online, Figure S5). 487 
This result suggests that the reduction in MCT1 level in the MCT1+/- hearts is sufficient to 488 
decrease succinate efflux. 489 
 490 
 491 
4. Discussion  492 
The accumulation of succinate during ischemia and its oxidation upon reperfusion is a key 493 
driver of I/R injury.1–5 While succinate is made within the mitochondrial matrix during 494 
ischemia, most succinate will be present in the cytosol at the onset of reperfusion. In addition, 495 
it is also clear that upon reperfusion some of the succinate accumulated during ischemia is 496 
released from the tissue upon reperfusion.2,6 Here we show that this succinate efflux from the 497 
cell is greatly enhanced by the pH gradient (acidic inside) between the tissue and the 498 
circulation upon reperfusion, and that this efflux is mediated by the monocarboxylate 499 
transporter, MCT1. The best understood role of MCT1 is as a plasma membrane lactate 500 
transporter, which leads to the electroneutral efflux of lactate along with a proton. At the low 501 
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pH (~6.5) within ischemic tissue,26,27 about 10% of the succinate will be in the 502 
monocarboxylate form (pKa ~ 5.6),33 which can then be transported by MCT1,28 presumably 503 
because of its similarity in structure to lactate. In addition, because MCT1 transports a 504 
monocarboxylate in symport with a proton, the pH gradient between the tissue and the 505 
circulation present upon reperfusion of the ischemic tissue will also drive succinate efflux. 506 
This model of succinate efflux, which was first suggested by Halestrap and colleagues,28 is 507 
shown in Figure 7. Importantly, this work shows that the succinate accumulated in the heart 508 
during ischemia has two fates: it is either oxidised by the mitochondrial respiratory chain, or 509 
it is released into the circulation, potentially acting as a metabolic signal. A precedent for 510 
such signalling is when circulating succinate is taken up and activates thermogenesis in 511 
brown adipose tissue14. elucidate the mechanism of succinate efflux from the ischemic heart 512 
during reperfusion raises the prospect of targeting MCT1-dependent succinate in heart attack. 513 
The kinetics and current understanding of succinate transport by MCT1 is poor. Whilst some 514 
initial characterisation of this process has been carried out,28 more complete experiments are 515 
required to understand the interplay of the pH gradient and succinate transport.  516 
 There are a number of experimental points that should be considered in interpreting 517 
our findings. Perfused heart experiments have a number of limitations, such as the use of 518 
supra-physiological concentration of glucose and the lack of fatty acids or other physiological 519 
respiratory substrates. However, it should be noted that an isolated perfused heart which was 520 
supplied with fatty acids as an energy source accumulates succinate to a similar extent as 521 
hearts perfused with glucose-containing medium.4 The second is that ischemic hearts in vivo, 522 
which had been perfused with blood prior to ischaemia and were thus respiring on 523 
physiological substrates, also accumulate succinate to the same extent as the isolated perfused 524 
heart.4,5 The third point is that reperfusion of the ischaemic human heart,2 or pig heart (this 525 
work), in vivo with blood leads to similar efflux of succinate. Thus, our in vitro heart 526 
perfusion system shows similar succinate accumulation during ischemia and efflux upon 527 
reperfusion as the heart in vivo.  528 
The potential role of succinate efflux as a signal from the ischemic tissue is supported 529 
by the fact that its efflux is carrier mediated, that succinate accumulates dramatically within 530 
ischemic tissues, the pH within ischemic tissues is lowered. The accumulation of succinate 531 
during ischemia seems to be a universal phenomenon and has now been shown by us and 532 
many others for hearts from mice, rats, rabbits, pigs and humans.1-5 Importantly, this 533 
accumulation of succinate during ischemia also occurs in vivo within tissues utilising 534 
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endogenous substrates, as well as in the Langendorff model, presumably because during 535 
ischemia the heart relies on glycogen as its main energy source.1-5,39  536 
The succinate efflux from the ischemic mouse hearts in vivo and ex vivo was 537 
associated with a limited number of other metabolites. The metabolome of the pig heart 538 
attack model mirrored that seen in STEMI patients,2 suggesting a conserved mechanism of 539 
release of these metabolites from the ischemic heart during reperfusion, with succinate being 540 
particularly elevated in both pigs and humans. We note that the pig is a widely used model 541 
for human cardiac metabolism, and importantly these were young, healthy animals analysed 542 
under tightly controlled conditions, compared to the human subjects1,2 who were all suffering 543 
from cardiac disease. Hence these data indicate that the succinate efflux in the human 544 
subjects was not simply a consequence of pathology. Lactate was prominent in the perfusate 545 
from mouse, a metabolite surprisingly not significantly elevated in the human plasma.2 This 546 
difference may be due to global ischemia in the Langendorff heart compared to regional 547 
ischemia in the heart attack models, or due to the high levels of lactate already present in the 548 
plasma masking changes.  549 
The action of succinate ligating its cognate receptor, SUCNR1 and subsequent 550 
immune activation during I/R injury by succinate released upon reperfusion may contribute 551 
to the damage associated with I/R injury (Figure 7).8,9,40,41 However, the pathological role of 552 
succinate efflux and the signalling that occurs on ligation to SUCNR1 are currently unknown.  553 
Furthermore, inhibition of succinate efflux upon reperfusion with MCT1 inhibitors might be 554 
expected to elevate tissue succinate oxidation and thus exacerbate I/R injury. To test this 555 
possibility, we carried out a preliminary experiment to assess the effect of the MCT1 556 
inhibitor AR-C141990 on cardiac I/R injury in an in vivo mouse model of cardiac I/R injury 557 
(Figure S6). Administration of AR-C141990 upon reperfusion was protective, despite the 558 
elevated tissue levels of succinate it caused in the isolated perfused heart (Figure S4). Further 559 
work is required to understand the mechanistic basis of this protection. One possibility is that 560 
the lack of lactate efflux has an impact on the cell, perhaps by its impact on glycolytic flux or 561 
cell pH. One possibility is that these factors disrupt mitochondrial succinate oxidation or 562 
ROS production during reperfusion. Future work will be required to determine fully the 563 
(patho)physiological roles of MCT1-dependent succinate efflux.  564 
 565 
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FIGURE LEGENDS 751 
 752 
Figure 1 Schematic of metabolite changes occurring during reperfusion.  753 
Upon reperfusion, succinate is oxidised producing ROS fed by succinate re-entry into 754 
mitochondria. We favour RET at complex I as the mechanism of this ROS production. Some 755 
of the succinate is also released from the cell. SDH, succinate dehydrogenase; RET, reverse 756 
electron transport; FH, fumarate hydratase; DIC, dicarboxylate carrier. 757 
 758 
Figure 2 (A-F) Succinate accumulation and efflux from the ischemic Langendorff heart and 759 
primary cardiomyocytes. (A) Langendorff model experimental design of ischemia and 760 
reperfusion. (B) Time dependent succinate accumulation in a Langendorff perfused mouse 761 
heart exposed to 10 or 20 min global no-flow ischemia ± 6 min reperfusion (mean ± S.E.M., 762 
n=3-8). Statistical significance was assessed by one-way ANOVA with Tukey’s post hoc test 763 
(**p <0.01, **** p <0.0001 *relative to equilibration, p <0.0001 relative to 10 min 764 
ischemia). (C-D) Succinate efflux from the Langendorff heart exposed to 10 or 20 min 765 
ischemia over the first 6 min of reperfusion (C) and compared to the succinate levels 766 
achieved in the heart exposed to 20 min ischemia (D) (mean ± S.E.M., n=5-8). (E) Succinate 767 
accumulation and efflux in primary cardiomyocytes exposed to anoxia (1 h) ± reperfusion (15 768 
min) (mean ± S.E.M., n=4-6). Statistical significance was assessed by one-way ANOVA with 769 
Dunnett’s post hoc test **** p <0.0001, relative to control (Ctl) values). (F) ROS production 770 
by RET in isolated heart mitochondria. Isolated rat heart mitochondria were incubated with 771 
varying succinate concentrations and where indicated rotenone (0.5 µM), and the production 772 
of H2O2 measured by the conversion of Amplex Red to resorufin (mean ± S.E.M., n=3). The 773 
EC50 for dependence of ROS production by RET on succinate concentration is shown. 774 
 775 
Figure 3 (A-B) Succinate is selectively effluxed from the ischemic heart upon reperfusion (A) 776 
Release of metabolites in the reperfusion coronary effluent (1-3 min) from the Langendorff 777 
heart, compared to equilibration coronary effluent expressed as cardiac release ratio 778 
([reperfusion-equilibration]/equilibration). (B) Plot showing -log10 of the adjusted p value 779 
plotted against the difference in normalised ion counts between equilibration and 1-3 min 780 
reperfusion coronary effluent (n=5). Plot generated in Prism 8.0 using multiple t-tests 781 
corrected for multiple comparisons using the Holm-Sidak method. 782 
 783 
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Figure 4 (A-F) Succinate accumulation and efflux from the ischemic heart in situ and in vivo. 784 
(A) Succinate accumulates during 20 min ischemia and rapidly returns to baseline values after 785 
6 min reperfusion in a murine in situ perfusion model (mean ± S.E.M., n=3). Statistical 786 
significance was assessed by one-way ANOVA with Dunnett’s post hoc test (*** p <0.001, 787 
relative to control (Normoxia) values). (B-C) Succinate efflux from the in situ perfused heart 788 
exposed to 20 min ischemia over the first 6 min of reperfusion (B) and compared to the 789 
succinate levels achieved in the heart exposed to 20 min ischemia (C) (mean ± S.E.M., n=3). 790 
(D) Schematic of porcine MI model and coronary sinus blood sampling (E). Succinate is 791 
elevated during early reperfusion in the coronary sinus in a porcine MI model. The LAD was 792 
occluded by gentle snaring for 60 min before snare released and blood sampled (mean ± 793 
S.E.M., n=3). Statistical significance was assessed by two-way ANOVA with Tukey’s post 794 
hoc test (**p <0.01, **** p <0.0001). (F) Release of metabolites in the coronary sinus at 795 
reperfusion (1-5 min) compared to aortic root blood expressed as cardiac release ratio 796 
([coronary sinus-aortic root]/aortic root) in porcine MI model. 797 
 798 
Figure 5 Modulating succinate efflux during reperfusion. (A) Succinate is structurally similar 799 
to phenylsuccinate and succimer. (B-C) Langendorff mouse hearts were exposed to 20 min 800 
global no-flow ischemia, before reperfusing for 6 min and the succinate measured in the 801 
perfusate collected during each minute of reperfusion. Control reperfusion from Figure 2B 802 
(n=5) and non-specific transport inhibitors added at 1 mM succimer (n=3) and 1 mM 803 
phenylsuccinate (n=3) at the onset and during reperfusion. (C) Mouse hearts were exposed to 804 
ischemia as in Figure 5B but reperfused with buffer at pH 6 (n=5). (D) Diagram of the 805 
mechanism of action of ionophores gramicidin, monensin and nigericin. (E) Mouse hearts 806 
were exposed to ischemia as in Figure 5B but reperfused in the presence of ionophores for 6 807 
min (all at 10 µM): gramicidin (n=5), monensin (n=4), nigericin (n=4). All data (B,C,E) are 808 
presented as mean ± S.E.M.) and statistical significance was assessed by two-way ANOVA 809 
with Dunnett’s post hoc test (*p <0.05, **p <0.01,*** p <0.001, ****p <0.0001 relative to 810 
control reperfusion). 811 
 812 
Figure 6 Succinate efflux during reperfusion is mediated by MCT1. (A-B) Langendorff 813 
hearts were treated as in Figure 5 but reperfused in the presence of either (A) 10 mM L-814 
lactate (n=5) or (B) 1, 10 or 50 µM AR-C141990 (MCTi; n=3-5). AR-C141990 was also used 815 
as a pre-treatment by infusing it during the equilibration phase prior to inducing ischemia 816 
(MCTi-Pre at 50 µM; n=5) (all mean ± S.E.M.). Statistical significance was assessed by two-817 
 27 
way ANOVA with Dunnett’s post hoc test (*p <0.05, ** p <0.01, ***p <0.001, ****p 818 
<0.0001 relative to standard reperfusion). (C) Succinate efflux from MCT1+/- and MCT+/+ 819 
mouse hearts exposed to 20 min ischemia upon reperfusion. (mean ± S.E.M., MCT+/+ n=7, 820 
MCT+/- n=5). Statistical significance was assessed by two-way ANOVA with Dunnett’s post 821 
hoc test (*p<0.05, **p <0.01 relative to MCT1+/+ reperfusion). 822 
 823 
Figure 7 Model of the mechanism of succinate efflux from the ischemic heart during 824 
reperfusion. In the ischemic cardiomyocyte, succinate protonation to a monocarboxylate is 825 
favoured by the more acidic intracellular pH. During reperfusion, the intracellular pH is 826 
restored by proton efflux due to the proton gradient across the plasma membrane. Here, 827 
succinate monocarboxylate together with a proton is effluxed from the cardiomyocyte by 828 
MCT1, reducing intracellular succinate levels. Succinate release upon reperfusion may be a 829 
signal of tissue ischemia and/or damage. SUCNR1 is a G-protein coupled succinate receptor 830 
that can respond to the succinate released into the circulation. SUCNR1 is highly expressed 831 
on the surface of immune cells and its ligation has been associated with a range of both pro- 832 
and anti-inflammatory phenotypes, depending on context. 833 
 834 
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SUPPLEMENTARY FIGURE LEGENDS 
 
Figure S1 Succinate efflux in a porcine MI model only occurs from the ischemic tissue. Pigs 
were treated as in Figure 4E: succinate is elevated during early reperfusion in the coronary 
sinus plasma but not jugular vein or aortic root in a pig heart attack model. The LAD was 
occluded by a balloon catheter for 60 min before removing the occlusion and blood sampled 
(mean ± S.E.M., n=3). Statistical significance was assessed by two-way ANOVA with 
Tukey’s post hoc test (**p <0.01, ****p <0.0001). 
 
Figure S2 Succinate is retained in the heart when reperfused with nonspecific transport 
inhibitors. Succinate levels in hearts after 6 min reperfusion with 1 mM succimer or 1 mM 
phenylsuccinate (Phsucc) from Figure 5B were measured (mean ± S.E.M., n=3-5). Statistical 
significance was assessed by two-way ANOVA with Dunnett’s post hoc test (****p <0.0001 
relative to control reperfusion). 
 
Figure S3 MCT1 inhibition or haploinsufficiency does not affect succinate accumulation. 
Hearts were perfused in Langendorff mode and equilibrated with Krebs buffer alone, or for 
MCTi-pre with 50 µM AR-C141990 for 20 min, before 20 min global no-flow ischemia and 
snap freezing tissue for succinate quantification by LC-MS/MS (mean ± S.E.M or mean ± 
range for MCT1+/-; WT n=8 (from Figure 2A), MCT1+/- n=2, MCTi-pre n=4). 
 
Figure S4 Succinate is retained in the heart when reperfused with MCTi. Succinate levels in 
hearts after 6 min reperfusion with MCTi from Figure 6B were measured (mean ± S.E.M., 
n=3-5). Statistical significance was assessed by two-way ANOVA with Dunnett’s post hoc 
test (****p <0.0001 relative to control (ctl) reperfusion). 
 
Figure S5 Succinate retained in the heart after reperfusion in MCT1+/- mice is no different 
from MCT1+/+ hearts. Succinate levels in MCT1+/+ and MCT1+/- hearts after 6 min 
reperfusion from Figure 6C were measured (mean ± S.E.M., MCT1+/+ n=7, MCT+/- n=5). 
 
 






Figure S6 Inhibition of MCT1 with AR-C141990 decreases cardiac ischemia-reperfusion 
injury. Anesthetized mice were subjected to occlusion of the LAD for 30 min and then the 
occlusion was removed and the hearts were reperfused for 120 min. The mice were infused 
IV for 20 min from 5 min before reperfusion with either saline, or saline supplemented with 
the MCT1i AR-C141990, at a total delivered dose of 1.5 mg/kg body weight. Infarct sizes 
were determined histologically as a percentage of risk area. Data are mean ± S.E.M., n=5. 
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